Spoerl, Steffen and Erber, Ramona and Gerken, Michael and Taxis, Juergen and Ludwig, Nils and Nieberle, Felix and Biermann, Niklas and Geppert, Carol Immanuel and Ettl, Tobias and Hartmann, Arndt and Beckhove, Philipp and Reichert, Torsten E. and Spanier, Gerrit and Spoerl, Silvia (2023) A20 as a Potential New Tool in Predicting Recurrence and Patient's Survival in Oral Squamous Cell Carcinoma. CANCERS, 15 (3): 675. ISSN , 2072-6694
Full text not available from this repository. (Request a copy)Abstract
A20, known as a potent inhibitor of NF-kappa B signaling, has been characterized in numerous clinical as well as preclinical studies. Recently, especially in various malignant diseases, the prognostic and therapeutic relevance of A20 was investigated. In oral squamous cell carcinoma (OSCC) however, the characterization of A20 is uncharted territory. We analyzed a tissue microarray (TMA) of 229 surgically-treated OSCC patients (2003-2013). Immunohistochemical (IHC) stainings were performed for A20 and CD3; additionally, standard haematoxylin-eosin staining was applied. IHC findings were correlated with a comprehensive dataset, comprising clinical and pathohistological information. A20 expression was analyzed in tumor cells as well as in tumor infiltrating lymphocytes (TILs) and correlated with the overall survival (OS) and recurrence-free survival (RFS) using uni- and multivariable Cox regression. The median follow-up time was 10.9 years and the A20 expression was significantly decreased in CD3+ TILs compared to mucosa-infiltrating lymphocytes (MILs). In the Kaplan-Meier analyses, higher A20 expression in TILs was correlated with better OS (p = 0.017) and RFS (p = 0.020). In the multivariable survival analysis, A20 overexpression correlated with improved OS (HR: 0.582; 95% CI 0.388-0.873, p = 0.009) and RFS (HR 0.605; 95% CI 0.411-0.889, p = 0.011). Our results indicate a novel prognostic role for A20 in OSCC. Due to its elevated expression in TILs, further research is highly desirable, which therefore could offer new therapeutic opportunities for patients suffering from OSCC.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | NF-KAPPA-B; INFLAMMATION; CANCER; INHIBITION; HEAD; TNF; oral squamous cell carcinoma; OSCC; A20; tissue microarray; TNFAIP3 |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Mund-, Kiefer- und Gesichtschirurgie Medicine > Zentren des Universitätsklinikums Regensburg > Tumorzentrum e.V. Medicine > Zentren des Universitätsklinikums Regensburg > Regensburger Centrum für Interventionelle Immunologie (RCI) Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Plastische-, Hand- und Wiederherstellungschirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 10 Mar 2024 14:11 |
| Last Modified: | 10 Mar 2024 14:11 |
| URI: | https://pred.uni-regensburg.de/id/eprint/59599 |
Actions (login required)
 |
View Item |
